Infliximab is a monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.
There is still a large unmet medical need for the treatment of ulcerative colitis, despite recent improvements in the understanding of the pathogenic mechanisms of ulcerative colitis.
A team of researchers at Sweden’s Karolinska Institutet studied how specific immune cells known as innate lymphoid cells (ILCs), which play a role in inflammatory bowel disease (IBD), evolve into mature cells.